anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: HPV is considered the most common sexually transmitted infection. It is responsible of 70% of cervical cancers worldwide. HIV infection is associated with increased rates of HPV infection. Women Living With HIV (WLWH) are 6 times at greater risk of developing cervical cancer. The current study aimed to estimate prevalence and identify genotypes of HPV infection among WLWH in Egypt compared to women with negative HIV status and determine associated risk factors.
METHODS: The study conducted among 251 WLWH and 268 women with negative HIV status enrolled from gynecological clinics in primary health care centers from nine Egyptian governorates. Data was collected from participants using a structured interview questionnaire and cervical samples were collected for HPV DNA detection and genotyping.
RESULTS: The overall prevalence of HPV infection was 13.5%, 3.4% among women with HIV negative status and 24.4% among WLWH. HR-HPVs other than genotype 16 and 18 were isolated from 71% of infected women. Woman's age, age at first marriage, number of lifetime marriages and drug addiction are significant predictors for HPV infection (odds 0.96, 0.91, 2.06, 2.01 respectively).
CONCLUSION: HPV infection is more prevalent among WLWH. Infection with HR-HPV other than genotype 16 and 18 was the most prevalent among infected women in both groups. Young age, early life sexual activity, having more than one sexual partner during the life time, and drug addiction are independent predictors for HPV infection. Having a husband who has had other sexual partners is significantly associated with infection.
Naloxone hydrochloride, an opioid antagonist, is a synthetic congener of oxymorphone. In structure it differs from oxymorphone in that the methyl group on the nitrogen atom is replaced by an allyl group. It is known chemically as 17-allyl-4,5α-epoxy,3-14-dihydroxymorphinan-6-one hydrochloride. It has a molecular weight of 363.84, and the following structural formula:

Naloxone hydrochloride occurs as a white to slightly off-white powder, and is soluble in water, in dilute acids, and in strong alkali; slightly soluble in alcohol; practically insoluble in ether and in chloroform.

Naloxone hydrochloride injection is available as a sterile solution for intravenous, intramuscular, and subcutaneous administration. Each mL contains 0.4 mg of naloxone hydrochloride. Each mL contains 8.9 mg of sodium chloride. The pH is adjusted between 3.0 to 6.5 with hydrochloric acid or sodium hydroxide. The air in the cartridges has been displaced by nitrogen gas.
Currently available blood tests for latent tuberculosis infection (LTBI) identify people who have been previously infected with M. tuberculosis. Whilst they are sensitive and specific, they cannot be used to monitor the effectiveness of treatment for LTBI. New blood tests ("fourth generation Quantiferon tests") give a more complete measurement of the workings of the immune system, which may be useful to show whether treatment is working. These new tests have not yet been evaluated in clinical practice, so their usefulness in identifying people at highest risk of TB disease and monitoring treatment is unknown.

Mass gatherings, such as the annual Hajj pilgrimage, may encourage the spread of infectious diseases, including respiratory infections such as influenza, respiratory syncytial virus, and possibly also tuberculosis. However, the risk of TB infection during the Hajj has not been reliably measured. It is important to measure this risk so that pilgrims can be given suitable advice about preventing infection.
An 8 mo old spayed female mixed-breed dog was presented for pale mucous membranes. The dog was diagnosed with intravascular immune-mediated hemolytic anemia (IMHA) and was started on medical management including corticosteroids, thromboprophylaxis, a packed red blood cell transfusion, and IV immunoglobulin. The dog developed severe hyperbilirubinemia (total bilirubin 48.1 mg/dL) and was referred for centrifugal plasmapheresis. Before treatment, the dog was stuporous to comatose, had intermittent opisthotonos, forelimb extension, and an absent menace consistent with acute bilirubin encephalopathy (ABE). The dog underwent a previously reported protocol of three therapeutic plasma exchange (TPE) treatments 24 hr apart. Moderate improvement was noted in her neurological status, although autoagglutination and hemolysis persisted, and the protocol was deemed inadequate. A fourth TPE treatment was performed on day 6. The following morning, the dog was autoagglutination negative. Her neurological status gradually improved, and she was discharged from the hospital on day 12. The dog remains neurologically normal and continues to do well at home on monotherapy with mycophenolate. Continued plasmapheresis treatments should be offered as a treatment option for severe cases of IMHA in the face of persistent disease, because TPE is able to provide ongoing support and stabilization, particularly in the face of ABE.
Stroke is a major cause of long-term disability in stroke survivors that related with motor impairment. After stroke, the cortical excitability of ipsilesional hemisphere is decreased; in contrast, the cortical excitability of contralesional hemisphere is increased. Conventional physical therapy is beneficial to motor recovery, but early rehabilitation was not always help the patients get full recovery. tDCS is an adjuvant tools which deliver weak direct current through scalp to promote motor recovery in stroke rehabilitation. The anodal-tDCS increases cortical excitability, while the cathodal-tDCS decreases cortical excitability. Previous studies demonstrated that both monocephalic techniques of tDCS can improve motor function in chronic, subacute, and acute phase, but it is still inconclusive that which monocephalic montages had better effect, especially in acute phase. There are several studies supported the benefits of monocephalic tDCS combined with rehabilitation programs on upper and lower limbs motor function in acute stroke. However, there is no evidence that directly compared the effect of monocephalic tDCS in acute stroke patients. The objective of the study is to compare the effects of anodal and cathodal tDCS combined with conventional physical therapy for 5 sessions on motor performance in acute stroke at immediate, and 1-month follow-up.
PROBLEM TO BE SOLVED: To obtain a suppository for treating rectum lesion tissue useful for treating rectum lesion tissue especially at the rectum or the anus. SOLUTION: This suppository contains an active component, consisting of tannic acid and aluminum potassium sulfate, and a base component for suppository. The suppository contains 0.6-60wt.% of the active component, 0.5-30wt.% of tannic acid and 0.1-30wt.% of aluminum potassium sulfate, each based on the suppository. The tannic acid is added at a ratio of 10-100wt.% based on the aluminum potassium sulfate. The suppository is effective not only for treating rectum lesion tissue attributable to light hemorrhoid, etc., but also it is effective on the postoperative complication at the rectum and the anus, that is, preventing the pain caused mainly by the postoperative spasms of sphincter, effecting bacteriostasis and antiinflammatory, allowing swellings to withdraw, stopping pain, stimulating normal and quick growth of granulation cells and accelerating the curing of the injured parts.  Further, the suppository can be easily applied at home. Since the active component has high safety and is dissolved in an organic liquid or a solid, the suppository is free from prophlogistic property, can be absorbed through the rectum mucous membrane and exhibits high curing activity.
A composition of natural antioxidants for prevention of deterioration of food, cosmetic and pharmaceutical products which contain polyunsaturated fatty acids comprising tocopherols, ascorbic acid, citric acid and phospholipids. The composition can further comprise rosemary extract. A composition of natural antioxidants for oils rich in tocopherols comprising ascorbic acid, citric acid and phospholipids is also disclosed. Rosemary extract can be added to this composition. A further composition of antioxidants in fish oil comprising tocopherols, ascorbic acids, citric acid, and de-oiled soybean phospholipids is also disclosed. Rosemary extract can also be added to this composition. A still further composition of antioxidants in a tocopherols rich vegetable oil comprises ascorbic acid, citric acid, and de-oiled soybean phospholipids. Rosemary extract can also be added to this composition. Several improvements to the phospholipids for use in the composition is also contemplated to provide the compositions with improved properties.
Participants in the BA group will receive BA treatment and treatment as usual. BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.
Gestational diabetes mellitus (GDM) is carbohydrate intolerance of varying degrees that begins during pregnancy or is first diagnosed during pregnancy. 4% of pregnancies are complicated by GDM. History of diabetes in first-degree relatives, history of GDM in previous pregnancies, body mass index over 30 kg/m2, significant weight gain during pregnancy, and maternal age over 25 are among the primary risk factors for gestational diabetes in pregnant women. Gestational diabetes; It causes serious maternal and fetal complications such as the risk of developing Type 2 diabetes in the mother, traumatic birth, preeclampsia, cesarean delivery, macrosomic baby, and congenital malformations.

It is known that healthy lifestyle behaviors are as effective as genetic factors in the development of diabetes. Lifestyle behavior modification is an essential component of gestational diabetes management. Studies show that 70-85% of pregnant women can control diabetes only with lifestyle changes. Protective health behaviors such as being at an ideal weight, eating healthy, exercising regularly and not smoking prevent the development of gestational diabetes. As a result of the Finnish Gestational Diabetes Prevention Study (RADIEL), it was found that physical activity and dietary intervention decreased the incidence of GDM by 36% in high-risk women. It is important that these preventive health behaviors are adopted and maintained by the pregnant woman. For this purpose, it is necessary to determine the problems in the process of acquiring behaviors that protect and improve health and prevent negative behaviors. Self-efficacy level plays an important role in initiating and maintaining preventive health behaviors. Education on preventive health behaviors can improve and improve self-care behaviors by increasing the self-efficacy level of women at risk of gestational diabetes.
1. A process for the preparation of a swallowable tablet of wet granulation containing 80-95% N-acetylcysteine by weight, 0.5-4.0% by weight with respect to N-acetylcysteine of a binder and optionally all or a part of the estimated amount of diluent and/or lubricant and further mixing of the granulate with remaining pharmaceutically acceptable excipients, the compression and the optional film-coating of the tablet. 2. A swallowable tablet according to claim 1 containing 80-95% N-acetylcysteine by weight, 0.5-4.0% by weight with respect to N-acetylcysteine of a binder and further pharmaceutically acceptable excipients. 3. A swallowable tablet according to claim 2 containing 80-95% N-acetylcysteine by weight, 1-3% binder by weight, 2.5-14% diluent by weight, 1-4.5% disintegrant by weight, 0.1-1.5% lubricant by weight optionally in the presence of a flowing agent and of a film-coating layer. 4. A swallowable tablet according to claim 2 or 3 containing 80-90% N-acetylcysteine by weight, 2-3% binder by weight, 3-14% diluent by weight, 1-4.5% disintegrant by weight, 0.1-1% lubricant by weight, 0.1-1% flowing agent and optionally a film-coating layer equal to or lower than 4% by weight. 5. A tablet according to one of the preceding claims 2 to 4, wherein the binder is selected among linearpolyvinylpyrrolidone, sodiumcarboxymethylcellulose, ethylcellulose, methylcellulose, liquid glucose, gelatine andhydroxypropylcellulose. 6. A tablet according to claim 4 wherein the binder is linear polyvinylpirrolidone. 7. A tablet according to one of the preceding claims 3 to 6, wherein the lubricant is selected among magnesium stearate, sodium stearyl fumarate, sodium benzoate and polyethylene glycol. 8. A tablet according to claim 7 wherein the lubricant is magnesium stearate. 9. A tablet according to one of the preceding claims 3 to 8, wherein the diluent is selected among carbohydrates, microcrystalline cellulose and derivatives thereof, inorganic salts, polyalcohols, and mixtures thereof. 10. A tablet according to claim 8, wherein the diluent is microcrystalline cellulose its derivatives or mixtures thereof. 11. A tablet according to one of the preceding claims 3 to 10, wherein the disintegrant is selected among cross-linkedpolyvinylpyrrolidone, sodium croscarmellose, sodiumcarboxymethyl starch, starch, pregelatinized starch and microcrystalline cellulose. 12. A tablet according to claim 10 wherein the disintegrant is cross-linked polyvinylpyrrolidone or sodium croscarmellose. 13. A tablet according to one of the preceding claims 3 to 12 containing colloidal silica as flowing agent.
MACS patients with AVS-confirmed bilateral cortisol overproduction and bilateral tumours will be included in this study group after signed study consent. EUS will be performed, and EUS-guided fine needle tissue sampling of the adenoma will be performed, before a subsequent EUS-RFA treatment procedure. Follow-up after 2 weeks, 3 months and 12 months for evaluation of clinical and biochemical outcome, and procedural complications.
OBJECTIVE: To assess the efficacy of the metal artifact reduction algorithm (MARA) of the Cranex 3D cone beam computed tomography (CBCT) device in the detection of peri-implant dehiscence and fenestration around zirconia implants.
STUDY DESIGN: In total, 60 implants were placed in bovine ribs. Dehiscence and fenestration defects were created around the implants, after which 60 CBCT images were obtained with and 60 without activation of MARA. Three radiologists examined the images for the presence of defects. The area under the curve (AUC) from receiver operating characteristic analysis, sensitivity, and specificity were calculated to assess the ability to discriminate the presence vs absence of bone defects. One-way analysis of variance was employed to analyze outcome measures. The significance level was established at 5% (α = 0.05).
RESULTS: AUC values indicated excellent discrimination of dehiscence on images with MARA activation and an excellent to outstanding range of discrimination with MARA deactivation. For fenestration, MARA activation and deactivation both led to outstanding discrimination. Sensitivity and specificity values revealed that activation of MARA was helpful in distinguishing the presence vs. absence of dehiscence, while both MARA conditions were helpful for fenestration. However, there were no statistically significant differences between MARA activation and deactivation for any outcome measure (P >.05).
CONCLUSION: CBCT is suitable for detecting peri-implant defects, but MARA application does not significantly affect peri-implant dehiscence and fenestration detection.
Ultrasound-guided posterior approach of glenohumeral space injection for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine.
On Day 1 and Day 15 of each 28-day cycle, participants receive an intravenous (IV) infusion of camrelizumab 200 mg Plus an oral apatinib 250 mg once daily. Apatinib will be administered 250 mg once every other day when completing twice tumor assessement. All treatments are administered until disease progression or unacceptable toxicity.
The compound of formula (III), where: The hatched segments represent a bonds, the solid triangle represents a b bond, and the dashed bond represents a double bond or a single bond. R5 is H or a lower alkyl radical having up to six carbon atoms. X is -OR1 or N(R1)2. Y is =O or represents two H radicals. R1 is H or a lower alkyl radical having up to six carbon atoms. Z is O and S. A is C or CR2. R2, R3 and R4 are independently H, halogen, cyano or lower alkyl having from 1 to 6 carbon atoms. The 9, 11 and 15 alkyl esters of the compound of formula (III) are also described. The following proviso applies to the compound of formula (III): When the depicted heteroaryl radical is a dichlorothienyl radical, a dibromothienyl radical or a bromo, methyl thienyl radical, the compound is not a 1-carboxylic acid or amide thereof. Also described is a compound of formula (I) useful for treating ocular hypertension, where: The hatched segments, solid triangle and dashed bond are as defined for formula (III). The wavy line attachment indicates either a or b configuration. R is a 5-membered substituted heteroaryl radical comprising one heteroatom selected from O and S and having at least two pendant substituents selected from C1-C6 alkyl, halogen, trifluoromethyl, COR1, COCF3, SO2NR1, NO2 and CN or at least one cyano group. X, Y and R1 are as defined for the compound for formula (III). The 9, 11 and 15 alkyl esters of the compound of formula (I) are also described. The following proviso applies to the use of the compound of formula (I): When the heteroaryl radical is a dichlorothienyl radical, a dibromothienyl radical or a bromo, methyl thienyl radical, the compound is not a 1-carboxylic acid or amide thereof. Also described is an ophthalmic solution comprising a therapeutically effective amount of the compound of formula (I). Also described is a pharmaceutical product comprising a container adapted to dispense the contents of the container in metered form, and the above described ophthalmic solution.
The permanently growing interest in amateur and professional sports activities among young, middle-aged and elderly athletes raises serious concerns about athletes' health, the safety of physical training, and the sports-related risk of sudden cardiac death and other cardiovascular complications during exercise. In recent years there has been an increasing number of cases of sudden cardiac death during physical effort. At present, life expectancy in the most developed countries grows rapidly and the number of people >65 years dramatically increases. Moreover, biological age of the population is lower. Subsequently, relevant increase in the number of elderly athletes involved in various types of sports activities has been reported in many countries. It was also demonstrated that physical activity has strong beneficial effect on cognitive functions, psychomotor performance and thus exercise capacity, which is very important for the elderly people in their everyday routine activities. Nonetheless, it should be remembered that participation in amateur and professional sports activities may be associated with risk of serious cardiovascular events in the elderly athletes often suffering from various civilization diseases. It is also reported that the number of elderly people after interventional cardiology procedures, open heart surgery and cancer treatment (chemotherapy, radiotherapy), who wish to participate in various sports activities, systematically grows. The authors of the paper conduct a literature review on cardiovascular risk assessment in the elderly athletes including the contemporary cardiology diagnostic methods and diagnostic schemes to prevent sudden cardiac death and other cardiovascular events during exercise. The controversies over efficacy of particular diagnostic tools to detect cardiovascular diseases in the elderly athletes and worldwide epidemiologic data concerning risk of sudden cardiac death during physical exercise have been also presented. Here, the authors have derived suggestions for establishment of comprehensive diagnostic schemes to prevent sudden cardiac death during sports activities. Med Pr Work Health Saf. 2024;75(3):233-241.
INTRODUCTION: Lower urinary tract symptoms (LUTSs) are a diverse array of urinary and pelvic dysfunctions that can emerge from childhood, extend through adulthood, and persist into older age. This narrative review aims to provide a comprehensive perspective on the continuum of LUTS and shed light on the underlying mechanisms and clinical implications that span across the lower urinary tract.
METHODS: A panel of five experts from Belgium, the Netherlands, India, Denmark, and the United States participated in an intensive research to explore and pinpoint existing insights into the lifelong concept of LUTS, particularly at the pelvic level. The experts reviewed the existing literature and held a webinar to discuss their findings.
RESULTS: Childhood LUTS can persist, resolve, or progress into bladder underactivity, dysfunctional voiding, or pain syndromes. The Lifelong character can be explained by pelvic organ cross-talk facilitated through complex neurological and nonneurological interactions. At the molecular level, the role of vasopressin receptors in the bladder's modulation and their potential relevance to therapeutic strategies for LUTS are explored. Frailty emerges as a parallel concept to lifelong LUTS, with a complex and synergistic relationship. Frailty, not solely an age-related condition, accentuates LUTS severity with insufficient evidence regarding the effectiveness and safety profile of the available therapeutic modalities.
CONCLUSION: Understanding lifelong LUTSs offers insights into genetic, anatomical, neurological, and molecular mechanisms. Further research could identify predictive biomarkers, elucidate the role of clinically translatable elements in pelvic cross-talk, and uncover molecular signatures for personalized management.
The invention provides a scutellarin sodium salt crystal I. The scutellarin sodium salt crystal I. Results of X-ray powder diffraction analysis, DSC and IR analysis show that the scutellarin sodium salt crystal I is a new crystal form; and the scutellarin sodium salt crystal I has the advantages of high purity, stability to light, humidity and heat, and good stability in an aqueous solution, and has higher solubility than scutellarin in water. The invention also provides a preparation method of the crystal. The method has the advantages of simple operation, low production cost, and easy industrial production. The content of scutellarin sodium salt in the scutellarin sodium salt crystal I reaches 98% or above.